Want to join the conversation?
$BIIB said aducanumab, its investigational treatment for early Alzheimer's disease, was granted Fast Track designation by the U.S. FDA. Aducanumab is being evaluated in 2 Phase 3 studies, ENGAGE and EMERGE, to evaluate its safety and efficacy in slowing cognitive impairment and progression of disability in people with early Alzheimer's disease.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.